Médecine
MENUJanus Kinase Inhibitors (JAKi). A new therapeutic class in the treatment of chronic inflammatory rheumatism Volume 16, issue 10, Décembre 2020
Authors
1 CHU Montpellier, Hôpital Lapeyronie, Service d’immunologie clinique et thérapeutique ostéo-articulaire, 291 avenue du Doyen Gaston Giraud, 34000 Montpellier
2 Institute for Regenerative Medicine and Biotherap (IRMB), Université de Montpellier, Inserm U1183
* Correspondance
- Key words: JAK inhibitors, inflammatory rheumatic diseases, rheumatoid arthritis, spondylarthritis, psoriatic arthritis
- DOI : 10.1684/med.2020.611
- Page(s) : 445-51
- Published in: 2020
The inhibition of pro-inflammatory cytokines has been since the era of biological drugs the basis for the treatment of many inflammatory diseases. The main mechanism of inhibition occurs through monoclonal antibodies targeting the causative cytokine or its receptor. However, another inhibition mechanism has been developed very recently, targeting intracellular signaling pathways using JAK or Janus Kinases. In this review, we will provide a brief description of JAK inhibitors and their mechanisms of action in the blood and immune system, followed by their prescription and monitoring modalities. Finally, we will discuss future prospects for this class of drugs in a growing spectrum of clinical indications.